Why AndroGel (testosterone topical) Causes Variable Absorption: The Mechanism Explained

At a glance

• Incidence of subtherapeutic or supratherapeutic levels: Approximately 16% of patients using AndroGel 1% failed to reach normal range in the key Phase III trial at the standard 5 g/day starting dose, requiring dose escalation (Steidle et al., 2003)
• Typical variability range: Published pharmacokinetic data show intra-individual coefficient of variation (CV) for Cmax of 26 to 34% and inter-individual CV exceeding 40% with topical testosterone formulations (Wang et al., 2000)
• Onset of absorption concern: Within the first steady-state window (days 2, 7 of consistent dosing)
• First-line management: Confirm application technique, dry clean skin, consistent body-site use, and recheck total testosterone trough at least 14 days after any dose change (Endocrine Society Guidelines, 2018)
• When to escalate: Persistently low trough (<300 ng/dL) or high trough (>1050 ng/dL) after technique correction, or symptoms inconsistent with measured levels
• When to discontinue/switch: Two consecutive failed dose adjustments with confirmed good technique; consider pellets, injections, or nasal gel as alternatives (Endocrine Society Guidelines, 2018)

---

The Skin Is Not a Passive Membrane

To understand why AndroGel levels fluctuate, you need to understand what testosterone is actually trying to cross. The outermost layer of skin, the stratum corneum, is roughly 10, 20 micrometers thick and composed of flattened, protein-filled corneocytes embedded in a lipid matrix of ceramides, cholesterol, and fatty acids. This architecture exists to prevent water loss and block external chemicals. Testosterone does not cross it easily.

Transdermal drug delivery depends on two primary diffusion routes through the stratum corneum: transcellular (through the corneocytes themselves) and intercellular (through the lipid lamellae between cells). For lipophilic molecules like testosterone, the intercellular route dominates. The rate of that diffusion is governed by Fick's first law, meaning flux is proportional to the concentration gradient and the diffusion coefficient within the lipid matrix. Anything that changes lipid composition, layer thickness, or surface area changes how much testosterone actually enters systemic circulation per unit of applied gel. A detailed review of these pathways is available in Prausnitz and Langer (2008).

AndroGel's hydroalcoholic gel vehicle is specifically engineered to exploit this route. The ethanol carrier increases lipid fluidity in the stratum corneum and acts as a penetration enhancer by temporarily disrupting the ordered lipid structure, driving testosterone into the tissue depot beneath. Once the ethanol evaporates (within minutes of application), a testosterone-rich film remains on the skin surface that continues to diffuse at a lower but sustained rate for the next several hours. This is why peak serum levels occur roughly 2 hours post-application and a quasi-steady state is reached by day 2 (Wang et al., 2000).

---

Why Absorption Varies: The Biological Mechanisms

Stratum Corneum Thickness and Lipid Composition

Skin thickness varies significantly by body region and by individual. The shoulders, upper arms, and abdomen (the FDA-approved application sites for AndroGel) all have meaningfully different stratum corneum properties. Abdominal skin in men with central obesity tends to have greater subcutaneous fat but not necessarily a thicker stratum corneum. However, obesity is associated with altered skin ceramide profiles and higher sebum production, both of which modify the lipid diffusion pathway for testosterone. Research published in the Journal of Investigative Dermatology confirms that regional variation in stratum corneum lipid composition directly affects permeation coefficients for lipophilic compounds.

Sebaceous Gland Density and Activity

Sebum output varies dramatically across body regions. The shoulders and upper arms carry higher sebaceous gland density than the inner thigh or abdomen in most men. Sebum is itself a lipid-rich secretion, and its presence can either enhance or impede transdermal absorption depending on its specific composition at a given time. Higher sebum production can temporarily increase skin surface lipophilicity, pulling more testosterone into the follicular route. Sebum production also varies with age, diet, season, and androgen status itself, creating a feedback variable that is nearly impossible to control clinically.

Skin Hydration

Hydrated skin absorbs more of almost everything. When the stratum corneum water content rises above roughly 50%, its structure becomes less ordered and diffusion coefficients increase substantially. This is why applying AndroGel immediately after a shower (to still-moist skin that has not been thoroughly dried) can produce a measurably higher absorption spike compared with applying to dry skin. The FDA-approved prescribing information for AndroGel 1% specifically instructs patients to allow the application site to dry completely before covering, partly to prevent transfer but also because premature occlusion traps moisture and alters the absorption profile unpredictably.

Occlusion and Clothing

Covering the application site with clothing before the gel has dried creates an occlusive microenvironment. Occlusion raises local skin temperature and moisture, which increases stratum corneum hydration and disrupts lipid packing. Studies on topical corticosteroids have shown that occlusion can increase percutaneous absorption by as much as 10-fold, and similar principles apply to testosterone gel. Wearing a tight shirt immediately after applying AndroGel to the shoulder can meaningfully shift the absorption curve, raising the early Cmax while also potentially reducing bioavailability if testosterone transfers to the garment rather than the skin.

---

Inter-Individual Pharmacokinetic Variability

The population-level data from the key AndroGel trials are revealing. In the Phase III registration study, men applying identical 5 g/day doses showed steady-state total testosterone levels ranging from below 300 ng/dL to above 1000 ng/dL. That is not a small spread. The investigators attributed the range to individual differences in skin permeability rather than compliance issues (Steidle et al., 2003).

Several biological variables drive this inter-individual spread:

Age-related skin thinning. The stratum corneum in older men (over 60) is thinner on average, but also has lower water content and altered lipid ratios. The net effect on absorption is not linear and varies by site, making dosing less predictable in this population.

Body mass index. Adipose tissue acts as a sequestration depot for lipophilic molecules. In men with high BMI, a fraction of the absorbed testosterone may partition into subcutaneous fat rather than entering the central compartment, reducing effective circulating levels relative to what would be predicted from in vitro permeation data. This mechanism is discussed in context of other lipophilic drugs in Hanley et al. (2010).

Skin microbiome and pH. Skin surface pH in healthy men averages around 4.5 to 5.5. Local inflammation, frequent washing with alkaline soaps, or dermatitis can shift this pH, altering stratum corneum protein structure and lipid ionization states. Some dermatological studies suggest alkaline skin pH increases permeability, though the clinical magnitude of this effect for testosterone specifically has not been rigorously quantified.

SHBG binding kinetics. Once testosterone crosses the dermis and enters capillary circulation, it binds rapidly to sex hormone-binding globulin (SHBG). Individual SHBG levels vary threefold to fivefold in the male population, meaning two men with identical free testosterone delivery from the skin may show very different total testosterone measurements. This is not an absorption variable per se, but it contributes heavily to the apparent variability seen on standard lab panels (Winters et al., 1998).

---

Application-Site Differences: What the Data Show

AndroGel is approved for the shoulders, upper arms, and abdomen. These sites are not pharmacokinetically equivalent. A pharmacokinetic comparison published in Clinical Endocrinology found that abdominal application produced higher and more variable serum concentrations compared with shoulder/arm application in the same subjects. The abdomen has thinner skin in many men, higher vascular density near the surface, and greater sensitivity to the hydration and temperature effects described above.

Scrotal application, which was used with older testosterone patch formulations, produces dramatically higher DHT concentrations due to the high local 5-alpha reductase activity in scrotal skin. AndroGel is explicitly contraindicated for scrotal application for this reason, as stated in the FDA prescribing information.

Rotating sites between applications, which some patients do to avoid local skin irritation, disrupts the steady-state absorption assumption entirely. If a patient applies to the right shoulder on Monday and the left abdomen on Tuesday, the pharmacokinetic profile shifts with each rotation.

---

Practical Steps to Reduce Variability in Real Time

The goal is to minimize the biological and behavioral sources of variability simultaneously:

1. Fix one site. Choose either both shoulders/upper arms or the abdomen and do not rotate between sites. This creates the most consistent skin environment from day to day.

2. Apply to dry, clean skin. Wait at least 5 minutes after toweling off from a shower. Soap residue and excess moisture both alter the stratum corneum state at the time of application.

3. Let the gel dry fully before dressing. A minimum of 5 minutes of air exposure is recommended in prescribing information, but 10 minutes is more conservative and reduces occlusion artifact.

4. Apply at the same time each day. Diurnal skin temperature and blood flow vary, and cortisol-related skin barrier fluctuations are highest in the early morning. Most practitioners recommend morning application to align peak levels with the body's natural testosterone peak and to make laboratory timing more predictable.

5. Time your lab draws correctly. The Endocrine Society recommends checking levels 2 hours after application for Cmax assessment and just before the next application for trough. Comparing a trough drawn on one visit to a peak drawn on another is a major source of apparent variability that is actually a measurement error (Bhasin et al., 2018).

6. Avoid swimming or showering for at least 6 hours post-application, as water exposure removes the surface film before absorption is complete (FDA prescribing information).

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

---

References

1. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology and Metabolism. 2003;88(6):2673-2681. PubMed

2. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Journal of Clinical Endocrinology and Metabolism. 2000;85(8):2839-2853. PubMed

3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. Full text

4. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology. 2008;26(11):1261-1268. PubMed

5. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clinical Pharmacokinetics. 2010;49(2):71-87. PubMed

6. Winters SJ, Kelly DE, Goodpaster B. The analog free testosterone assay: Are the results in men clinically useful? Clinical Chemistry. 1998;44(10):2178-2182. PubMed

7. Elias PM, Feingold KR. Skin barrier function. Journal of Investigative Dermatology Symposium Proceedings. 1992. Regional stratum corneum lipid variation. PubMed

8. U.S. Food and Drug Administration. AndroGel 1% (testosterone gel) prescribing information. Revised 2021. FDA.gov

9. Meikle AW, Arver S, Dobs AS, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site. Clinical Endocrinology. 1996;44(6):765-769. PubMed